Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
InFo Neurologie + Psychiatrie
Erschienen in: InFo Neurologie + Psychiatrie 12/2023

15.12.2023 | Sucht | Zertifizierte Fortbildung Psychatrie

Suchttherapie

Anticraving-Substanzen in der Therapie der Alkoholabhängigkeit

verfasst von: Dr. med. Johannes Kramer, PD Dr. med. Gabriele Koller, Prof. Dr. med. Oliver Pogarell

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 12/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Suchterkrankungen sind weltweit eine bedeutende sozialmedizinische Herausforderung. Sie können nicht nur unmittelbar zu schweren, oft dauerhaften Beeinträchtigungen der psychischen und körperlichen Gesundheit führen, sondern sind auch in hohem Maß mit komorbiden psychischen und körperlichen Störungen assoziiert. Pharmakotherapeutische Strategien können zur Abstinenzaufrechterhaltung und Prognoseverbesserung eine wichtige Ergänzung darstellen. …
Literatur
1.
Rauschert C et al. The use of psychoactive substances in Germany. Dtsch Arztebl Int. 2022;119(31-32):527-34
2.
Deutsche Hauptstelle für Suchtfragen e.V. Das DHS Jahrbuch Sucht 2023. Pabst Science Publishers; 2023
3.
World Health Organization (2021). Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision, German Modification, Version 2021, mit Aktualisierungen vom 11.11.2020 und 10.03.2021. In: Bundesinstitut für Arzneimittel und Medizinprodukte
4.
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (Dgppn), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (Dg-Sucht) (2021). S3 Leitlinie „Screening, Diagnose und Behandlung alkoholbezogener Störungen”. In: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
5.
Yeung EW, Craggs JG, Gizer IR. Comorbidity of alcohol use disorder and chronic pain: Genetic influences on brain reward and stress systems. Alcohol Clin Exp Res. 2017;1831-48
6.
Soyka M et al. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World J Biol Psychiatry. 2017;86-119
7.
Sliedrecht W et al. Alcohol use disorder relapse factors: A systematic review. Psychiatry Res. 2019;97-115
8.
Heinz A et al. Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol. 2003;35-9
9.
Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;1179-88
10.
Spanagel R et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med. 2005;35-42
11.
Rosner S et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;CD004332
12.
Sass H et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;673-680
13.
O'malley SS, Froehlich JC. Advances in the use of naltrexone: an integration of preclinical and clinical findings. Recent Dev Alcohol. 2003;217-45
14.
Bouza C et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;811-28
15.
Rosner S et al. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008; 11-23
16.
Maisel NC, Blodgett JC, Wilbourne PL et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;275-93
17.
Kiefer F et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;92-9
18.
Arias AJ et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008;1159-66
19.
Soyka M, Rosner S. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs. 2010; 1451-9
20.
Mann K, Bladstrom A, Torup L et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;706-13
21.
Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol. 2008;266-322
22.
Nutt D et al. Alcohol and the Brain. Nutrients. 2021; doi: 10.3390/nu13113938
23.
Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs. 2004;1105-18
24.
Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs. 2004;485-504
25.
Nunes EV, Levin FR. Treatment of co-occurring depression and substance dependence: Using meta-analysis to guide clinical recommendations. Psychiatr Ann. 2008;38(11):nihpa128505
26.
Hashimoto E et al. Influence of comorbid alcohol use disorder on treatment response of depressive patients. J Neural Transm (Vienna). 2015;301-6
27.
Johnson BA et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;963-71
28.
Johnson BA et al. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl). 2002;408-13
29.
Moore CF et al. Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats. Exp Clin Psychopharmacol. 2014; 35-42
30.
Lynch WJ et al. Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Psychopharmacology (Berl). 2011;3-12
31.
Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;34-56
32.
Johnson BA et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;1641-51
33.
Pani PP et al. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2014;2014(2):CD008544
34.
Heinz A et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry. 2005; 1515-20
35.
Volkow ND. Imaging the addicted brain: from molecules to behavior. J Nucl Med. 2004;45(11):13N-16N, 19N-20N, 22N passim
36.
Kishi T et al. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 2013;e642-54
37.
Croissant B et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry. 2006;570-3
38.
Martinotti G et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;417-24
39.
Guardia J et al. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 2011;265-9
40.
Voronin K et al. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm - possible influence of self-control. Alcohol Clin Exp Res. 2008;1954-61
41.
Anton RF et al. Aripiprazole suppression of drinking in a clinical laboratory paradigm: Influence of impulsivity and self-control. Alcohol Clin Exp Res. 2017;1370-80
42.
Fischler PV et al. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol. 2022;927703
43.
Soyka M et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 2008;317-24
44.
Addolorato G et al. Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol. 2009;559-63
45.
Addolorato G et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;1915-22
46.
Ameisen O. Treatment of alcohol-use disorders. Lancet. 2009;1519; author reply 1519-20
47.
Agabio R et al. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2023; CD012557
48.
Skinner MD et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014; e87366
49.
Mutschler J et al. Supervised disulfiram in relapse prevention in alcohol-dependent patients suffering from comorbid borderline personality disorder--a case series. Alcohol Alcohol. 2010; 146-50
50.
Brewer C, Streel E. Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive „immersion” methods of foreign language teaching. Subst Abus. 2003;157-73
51.
Mutschler J et al. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. 2016; 137-41
52.
Soyka M, Lieb M. Komorbidität von Depression und Alkoholabhängigkeit: Klinische und neurobiologische Aspekte. Nervenheilkunde. 2004;13-20
53.
Colpaert K et al. Impact of addiction severity and psychiatric comorbidity on the quality of life of alcohol-, drug- and dual-dependent persons in residential treatment. Eur Addict Res. 2013;173-83
54.
Berglund M et al. Treatment of alcohol abuse: an evidence-based review. Alcohol Clin Exp Res. 2003;1645-56
55.
Green AI et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat. 2008;61-71
56.
Drake RE. Management of substance use disorder in schizophrenia patients: current guidelines. CNS Spectr. 2007;27-32
57.
Green AI et al. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007; 402-8
58.
Soyka M et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;362-72
Metadaten
Titel
Suchttherapie
Anticraving-Substanzen in der Therapie der Alkoholabhängigkeit
verfasst von
Dr. med. Johannes Kramer
PD Dr. med. Gabriele Koller
Prof. Dr. med. Oliver Pogarell
Publikationsdatum
15.12.2023

Weitere Artikel der Ausgabe 12/2023

InFo Neurologie + Psychiatrie 12/2023 Zur Ausgabe

Info Pharm

Anfallsprophylaxe so früh wie nötig

Journal club

Nikotinpflaster können den Verlauf der Parkinsonkrankheit nicht bremsen

Journal club

Weiterer Komplementinhibitor bei generalisierter Myasthenia gravis

Info Pharm

Beträchtlicher Zusatznutzen für Fenfluramin

Journal club

Amyloidantikörper bremst kognitiven Verfall

Aktuell

Amyotrophe Lateralsklerose: Reduktion der Progressionsrate unter Antisense-Oligonukleotid?
Bildnachweise